Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In episode 2 of an ongoing series of sharing sessions between a physician and patient, Robert Gish, MD, FAASLD, and patient advocate, Alan Wang, discuss stigma as a barrier to optimal HBV care and treatment. The conversation focuses on how stigma affected Alan’s engagement with his care and strategies to overcome stigma as a barrier to HBV care.
Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
University of Nevada Reno School of Medicine
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Hepatitis B Foundation
This program has been made available online.
Review key slides on the interplay of COVID-19 and viral hepatitis and review expert strategies for managing chronic liver disease in the COVID-19 era
Clinical Care Options (CCO) commentary by Dr. Dominique Braun on the results of the Swiss HCVree Trial: HCV testing, treatment, and counseling in MSM with HIV and HCV
Clinical Care Options (CCO) and Dr. Robert Gish: Interplay of COVID-19 and viral hepatitis, expert strategies for chronic liver disease in the COVID era
Download slides reviewing the latest data and guidance on approaches to managing patients with hepatitis delta virus (HDV), from Clinical Care Options (CCO)